Clinical Trial Update: ADAM-Afatinib Diarrhea Assessment and Management [Phase 3]

View source ↗

Summary

This Phase 3 trial update reports on the incidence and management of diarrhea associated with afatinib in patients with non-small cell lung cancer in the ADAM s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Giotrif (afatinib)

Snippet

Sponsor: Boehringer Ingelheim | Conditions: Carcinoma, Non-Small-Cell Lung | Phase 3 | Status: COMPLETED | Results posted: 2016-10-31